Nucleus RadioPharma

Executive Summary

Nucleus RadioPharma is a full-service contract development and manufacturing organization (CDMO) exclusively focused on radiopharmaceuticals. Founded in 2021 and headquartered in Rochester, MN, the company provides end-to-end services to accelerate targeted radiotherapies from research through commercial supply. With the radioligand therapy market projected to grow rapidly, Nucleus is strategically positioned to support innovators in theranostics and targeted alpha/beta therapies. The company aims to address critical supply chain bottlenecks by building robust clinical and commercial manufacturing capabilities. While still private and early-stage, Nucleus has the potential to become a key partner in the radiopharma ecosystem, leveraging the expertise from its Minnesota base, a hub for nuclear medicine innovation.

Upcoming Catalysts (preview)

• Q1 2027Announcement of a major pharma partnership or multi-year supply agreement60% success
• Q3 2026Expansion of manufacturing capacity (e.g., new facility or hot cell installation)70% success
• Q4 2026Successful FDA pre-approval inspection for a client's radiopharmaceutical50% success